For generations, the statin tablet has stood as medicine's primary answer to the silent accumulation of cholesterol in human arteries — yet no single tool fits every hand that reaches for it. In Delhi, a cardiologist has drawn attention to injectable therapies that work through an entirely different biological pathway, offering a considered alternative for those whom the standard approach has failed or cannot serve. These treatments — PCSK-9 inhibitors and the longer-acting Inclisiran — are not meant to replace the familiar pill, but to extend the reach of care to those left behind by it. The
Hindustan Times
· Jun 28, 2026
· health
· 2 min read
Medium
Sourcing: Characterized
When Cholesterol Injections Beat Pills: Delhi Cardiologist's Guide
◉
Health & Medicine
9228 related articles
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% match
Uganda declares victory over Ebola as last patient discharged
BBC News · 99% match
Experimental drug shows early promise for treatment-resistant prostate…
Medical Xpress · 99% match
Should low-risk tumors still be called cancer?
The Irish Times · 99% match
WHO warns cancer kills 26,000 daily as Nigeria expands patient support
The Guardian Nigeria News · 99% match
Related Coverage
Google News · Sep 11
CDC reports 17% spike in rabies cases during summer months
The CDC reported a 17% increase in rabies cases during July and August, prompting public health warnings and emergency r…
News-Medical · Sep 11 Ketogenic Therapy Shows Early Promise for PTSD, But Clinical Evidence Remains LimitedAn integrative review found ketogenic therapy may influence metabolic and inflammatory pathways linked to PTSD, with ani…
Chemeurope · Sep 11 XPS Surface Analysis Unlocks Bio-Based Hybrid Material Chemistry for Water TreatmentResearchers use X-ray photoelectron spectroscopy to analyze surface chemistry of bio-based hybrid materials made from wa…
respiratory-therapy.com · Sep 11 WHO Links Tobacco Use to Reduced Fertility GloballyWHO warns that tobacco use significantly reduces fertility outcomes worldwide, affecting conception likelihood across po…
Bias & Framing
⚖
Article presents medical information from a Delhi cardiologist about injectable cholesterol therapies with minimal apparent bias, though lacks critical cost/accessibility discussion and alternative perspectives.
Bias Direction
center
Confidence
MED
Expert authority framing - relies heavily on single cardiologist's perspective presented as definitive guidance; positions injectable therapies as legitimate medical advancement without critical examination of limitations
safe and effective option
biggest risk factors
significantly higher risk
more convenient dosing schedule
Patient cost burden and insurance coverage barriers for expensive injectable therapies
Perspectives from other cardiologists or medical institutions on treatment protocols
Potential side effects or limitations of PCSK-9 inhibitors and Inclisiran
Accessibility issues in India where these therapies may be prohibitively expensive
Lifestyle modification alternatives or complementary approaches
Pharmaceutical industry influence on treatment recommendations
Geopolitical Impact
🌎
Medical article about cholesterol injection therapies has no geopolitical implications.
Escalation Risk
N/A
Confidence
HIGH
Economic Lens
📈
Injectable cholesterol therapies (PCSK-9 inhibitors and Inclisiran) are emerging alternatives to statins for specific patient groups, potentially expanding the pharmaceutical market for cardiovascular treatments in India.
Market Signal
bullish
Confidence
MED
Pharmaceutical manufacturing and distribution
Healthcare services and cardiology
Medical devices and injectable delivery systems
Health insurance and reimbursement
Patients with statin intolerance or inadequate response gain treatment alternatives, but likely face higher out-of-pocket costs due to premium pricing of injectable therapies, potentially creating affordability barriers for middle and lower-income households.
Indian regulators may need to review pricing controls, insurance coverage mandates, and reimbursement policies for these expensive biologics. Government health schemes (Ayushman Bharat) may face pressure to include these therapies, impacting public healthcare budgets.